Caption Management’s Travere Therapeutics TVTX Stock Holding History

Caption Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,000	Closed	-$1.11M	–	2054
2026 Q1	$743K	Buy	+25,000	New	+$747K	﹤0.01%	1104
2025 Q4	–	Sell	-60,193	Closed	-$1.96M	–	2074
2025 Q3	$1.44M	Buy	+60,193	New	+$1.13M	0.01%	974
2024 Q3	–	Sell	-28,011	Closed	-$292K	–	1592
2024 Q2	$230K	Buy	28,011 +11,204	+67%	+$75.5K	﹤0.01%	937
2024 Q1	$130K	Buy	+16,807	New	+$142K	﹤0.01%	1036
2022 Q4	–	Sell	-10,200	Closed	-$251K	–	1723
2022 Q3	$251K	Buy	+10,200	New	+$264K	﹤0.01%	1212

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caption Management's TVTX Position: Q2 2026 in Review

Caption Management sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 25,000 shares — an estimated $1.11M sold.

Caption Management first reported a position in TVTX in Q3 2022 and held it in 5 quarters. The position peaked at $1.44M in Q3 2025. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Caption Management reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
Caption Management sold 25,000 Travere Therapeutics shares in Q2 2026, an estimated $1.11M.
Caption Management first reported a position in Travere Therapeutics in Q3 2022 and held it in 5 quarters.
Caption Management's Travere Therapeutics position peaked at $1.44M in Q3 2025.
320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.